AlzeCure Pharma: AlzeCure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-opioid ACD440

STOCKHOLM, SE / ACCESSWIRE / May 24, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

Related Keywords

Sweden ,Stockholm ,Swedish ,Alzecure Pharmaview ,Gewinn Nur ,Alzecure Pharma ,Martin Marta , ,Nobel Prize ,Nasdaq First North Premier Growth Market ,Big Pharma ,Alzecure ,Dharma ,Nnounces ,Positive ,Hase ,Linical ,Study ,Data ,Neuropathic ,Rain ,Opioid ,Cd440 ,